Prepared and published by Update Software Ltd . All rights reserved. Cochrane reviews are regularly checked and updated if necessary. Hepatocellular carcinoma is an important disease in particular geographic areas such as in the Far East, east Africa and the Mediterranean region.
Surgery is the treatment of choice but even then there is a high recurrence rate.
This is the motivation for investigating all forms of adjuvant therapies to supplement surgery. A total of eight randomised controlled clinical trials were identified, totaling 548 randomised patients. The remaining trial reported only the mean survival times. None reported the hazard ratio and only one did a sample size calculation. None were comparable in terms of both treatment regimen and participants selected, so no pooling was done.